Alexandria Real Estate Equities, Inc. CEO Joel Marcus Appointed To BIO Board

PASADENA, Calif., July 13, 2015 -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Chairman, Chief Executive Officer, and Founder Joel S. Marcus has been appointed to the Biotechnology Industry Organization (BIO) Board of Directors for the 2015-2016 term, and will also serve on the Emerging Companies Section Governing Board.

"Joel and I have worked together over the last two decades supporting the early growth and infrastructure of a number of life sciences companies," commented Ron Cohen, MD, President and Chief Executive Officer of Acorda Therapeutics, Inc., the Chair of the BIO Board of Directors for 2015-2016, and BIO Executive Committee member. "Alexandria has been a committed partner to life science companies and academia through its world-class office/laboratory space clustered in key life science hubs across the country, as well as its high-impact science, economic and policy focused summits, and its support for important health policy issues on Capitol Hill. As an investor in many private companies that completed their initial public offerings, Joel brings deep experience to BIO and our Emerging Companies Section Governing Board, and it is a pleasure to welcome him at this time."

On accepting his newly elected position, Mr. Marcus said, "I am honored to join the BIO Board and to continue supporting emerging companies at the forefront of scientific and medical innovations. Alexandria is committed to advancing the life science industry by fostering impactful collaborations and championing crucial life science policy issues to improve human health. Through Alexandria Venture Investments, Alexandria's strategic venture capital arm, we have invested in entrepreneurs and their companies, which are substantially and positively impacting the lives of patients. This is a mission-critical industry, which primarily focuses on improving the quality of healthcare, giving us a real opportunity to make a difference. We are honored to be a part of that effort."

Alexandria Venture Investments focuses on novel, breakthrough discoveries in biopharmaceuticals, diagnostics, research tools, agtech, digital health and technology. Since 1996, Alexandria Venture Investments has provided strategic investment capital to the science and technology industries.

Mr. Marcus brings extensive expertise and support to the BIO Board and to emerging companies as they develop and navigate policy issues. Mr. Marcus and Alexandria have had a longstanding commitment to providing the global life science community with meaningful ways to connect, collaborate and innovate through their unique thought leadership initiatives and forums. Founded in 2010, the Alexandria Summit® brings together Alexandria's diverse global network in interactive and intimate gatherings to stimulate groundbreaking ways of thinking; accelerate the discovery and development of life-saving, cost-effective therapies; and move the field forward. The Alexandria Summit fosters partnerships among leaders from life science, technology, non-profit, government and healthcare as they tackle the most critical global healthcare challenges and shape the future of life science research and development. As a BIO board member, Mr. Marcus will work to carry out BIO's mission efficiently and effectively to help prevent illness, save lives and improve the quality of life for patients.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc. is the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, with a total market capitalization of $11.3 billion as of March 31, 2015, and an asset base of 30.7 million square feet, including 18.5 million RSF of operating and current value-creation projects, as well as an additional 2.2 million square feet of near-term and 10.0 million square feet of future ground-up development projects. Alexandria pioneered this niche in 1994 and has since established a dominant market presence in AAA locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. Alexandria is known for its high-quality and diverse client tenant base, with approximately 52% of total annualized base rent as of March 31, 2015, generated from investment-grade client tenants – a REIT industry-leading percentage. Alexandria has a longstanding and proven track record of developing Class A assets clustered in urban science and technology campuses that provide its innovative client tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. For more information, please visit